Vyndaqel
(Tafamidis)ApprovedSmall molecule
Vyndaqel is a small molecule that works as a Transthyretin Stabiliser; Transthyretin Stabiliser.[2] It is being used across 7 indications, with its most advanced program in Approved.[1]
Vyndaqel is one of 108 small molecule programs targeting Cardiomyopathy. It is currently in Approved.
7
Indications
33
Total Trials
2
Active Trials
107
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
3
Patents
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
91 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Dobutrex
Eli LillyPhase 3
Plaquenil
Alnylam PharmaceuticalsPhase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Immunoglobulins
CSL BehringPhase 3
Cialis
Eli LillyPhase 2
Aldactone
PfizerPhase 2
Betaseron
BayerPhase 2
Cellcept
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
MPA8 trials
Show 5 more trials
Polyneuropathy4 trials
Transthyretin Amyloid Cardiomyopathy4 trials
Cardiomyopathy3 trials
9 more indications
Hereditary Transthyretin Amyloidosis2 trials
Amyloidosis2 trials
Oral1 trial
Interaction1 trial
Absorption1 trial
TED1 trial
Unspecified2 trials
Regulatory
FDA Approval Timeline[4]
May 3, 2019
VYNDAMAX
NDA NDA212161
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tafamidis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]